You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EMB-01，Tyrosine Kinase Inhibitor (TKI) Resistant

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

Recruiting
  • Liver Neoplasms
  • Tislelizumab plus tyrosine kinase inhibitor
  • Beijing, Beijing, China
    302 Hospital
Sep 22, 2023

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

Metabolic Alternation and Clinicohematological Characteristic in

Not yet recruiting
  • CML, Chronic Phase
  • Tyrosine kinase inhibitor
  • (no location specified)
Nov 6, 2023

HRQOL in Locally Advanced Thyroid Carcinoma

Recruiting
  • Thyroid Cancer
  • +2 more
  • Tyrosine kinase inhibitor drugs.
  • Fuzhou, Fujian, China
    Road Fuma No.420
Apr 11, 2023

Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)

Recruiting
  • Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
  • Topical Timolol
  • Hong Kong, Hong Kong
    Queen Mary Hospital
Nov 14, 2023

Condition Vasoregulation Function Endothelium in CML Getting TKI

Recruiting
  • Chronic Myeloid Leukaemia
  • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
  • Moscow, Russian Federation
  • +1 more
Jan 11, 2023

Non Small Cell Lung Cancer, Liquid Biopsy, Tyrosine Kinase Inhibitor Trial in Rotterdam

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
    • Rotterdam, Netherlands
      Erasmus MC
    Feb 2, 2022

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text

    Recruiting
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Chronic Phase Chronic Myelogenous Leukemia
    • Text Message-Based Navigation Intervention
    • Survey Administration
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Apr 7, 2022

    Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

    Not yet recruiting
    • Stage IIIA Hepatocellular Carcinoma
    • Radiotherapy combined with TKI and Anti-PD-1 Antibody
    • (no location specified)
    Sep 24, 2023

    Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer Trial in Duarte (other, dietary supplement, drug)

    Active, not recruiting
    • Diarrhea
    • +2 more
    • Laboratory Biomarker Analysis
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jun 7, 2022

    CML (Chronic Myelogenous Leukemia Trial (KDS-1001)

    Not yet recruiting
    • CML (Chronic Myelogenous Leukemia
    • (no location specified)
    Jul 27, 2022

    TKI Discontinuation in CML Patients of China

    Recruiting
    • Leukemia
    • +4 more
      • Shenzhen, Guangdong, China
        Shenzhen Second People's Hospital
      Mar 15, 2022

      Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Bempegaldesleukin, Axitinib)

      Active, not recruiting
      • Renal Cell Carcinoma
      • Nivolumab
      • +2 more
      • Springdale, Arkansas
      • +33 more
      Nov 22, 2022

      Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

      Recruiting
      • Non-Squamous Non-Small Cell Lung Cancer
      • Shanghai, Shanghai, China
        Shanghai Chest Hospital
      Sep 22, 2022

      Cancer, Cancer, Treatment-Related, Medication Adherence Trial in Chicago (Oncotool Intervention (symptom reporting + TKI

      Completed
      • Cancer
      • +4 more
      • Oncotool Intervention (symptom reporting + TKI education)
      • Oncotool Control (health information)
      • Chicago, Illinois
        Northwestern University
      Jan 25, 2023

      Outcomes of Tyrosine Kinase Inhibitor(TKI)Stopping in Chronic

      Recruiting
      • Folate
      • +2 more
        • Nantong, China
          Affliated Hospital of Nantong University
        Dec 13, 2021

        Diabetic Macular Edema Trial (EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)

        Not yet recruiting
        • Diabetic Macular Edema
        • (no location specified)
        Oct 19, 2023

        ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

        Completed
        Has Results
        • ALK-positive NSCLC
        • Sollentuna, Sweden
          Pfizer Innovations AB
        Mar 14, 2022

        MSS, pMMR, Metastatic Colorectal Adenocarcinoma Trial in Shenyang (TKI ± anti-PD-1 antibody)

        Recruiting
        • MSS
        • +2 more
        • TKI ± anti-PD-1 antibody
        • Shenyang, Liaoning, China
          Cancer Hospital of China Medical University/Liaoning Cancer Hosp
        Sep 28, 2021

        Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

        Recruiting
        • Hepatocellular Carcinoma Non-resectable
        • HAIC
        • +8 more
        • Quanzhou, Fujian, China
        • +1 more
        Jan 26, 2023

        NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • (no location specified)
        May 23, 2023

        Unresectable Hepatocellular Carcinoma Trial in Beijing (Camrelizumab, HAIC, TKI)

        Recruiting
        • Unresectable Hepatocellular Carcinoma
        • Beijing, Beijing, China
          Cancer Institute and Hospital, Chinese Academy of Medical Scienc
        Nov 22, 2021

        Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

        Not yet recruiting
        • Ovarian Cancer
        • +4 more
        • (no location specified)
        Aug 8, 2022

        Thyroid Cancer, Thyroid Cancer, Medullary, Differentiated Thyroid Cancer Trial in Tampa (Lenvatinib, Sorafenib, Cabozantinib)

        Terminated
        Has Results
        • Thyroid Cancer
        • +5 more
        • Tampa, Florida
          H. Lee Moffitt Cancer Center and Research Institute
        Jul 12, 2021

        Renal Cell Carcinoma Trial in Omaha, Cleveland, Philadelphia (Axitinib)

        Terminated
        Has Results
        • Renal Cell Carcinoma
        • Omaha, Nebraska
        • +2 more
        Jul 26, 2021